medigraphic.com

2018, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2018; 85 (1)

Uterine carcinosarcoma. A rare and deadly neoplasm

Vargas-Hernández VM, Vargas-Aguilar VM, Sosa-Durán EE, Aboharp-Hasan Z

Language: Spanish
References: 29
Page: 26-38
PDF size: 555.03 Kb.


ABSTRACT

Carcinosarcoma is a rare gynecological neoplasia that belongs among mixed Mullerian tumors. It has malignant epithelial and mesenchymal components, which can develop anywhere in the gynecologic tract, but it is more frequent in the uterine cavity, where it accounts for 5% of all malignant neoplasms. It is aggressive and has a poor prognosis; 30% present outside the uterus at the time of diagnosis. It is currently classified as carcinoma with elements of sarcomatous metaplasia. The diagnostic accuracy of tumor markers and imaging is limited. An endometrial biopsy is diagnostic in some patients. Classification and staging for uterine sarcomas was actualized in an attempt to reflect their different biological behavior. The incidence of regional lymph node metastases is high, and pelvic and paraaortic lymphadenectomy are typically performed for staging and treatment. In women with advanced carcinosarcoma, optimal surgical cytoreduction is suggested. Chemotherapy (Qt) with pelvic radiotherapy (Rt) or vaginal brachytherapy adjuvant with optimal cytoreduction are used in stages Ib-IVa.


REFERENCES

  1. Vargas HM, Hernández RA, Jiménez VX. Sarcoma del útero. En: Vargas-Hernández VM, editor. Cáncer en la Mujer. México: Edit. Alfil; 2011. pp. 1039-46.

  2. Vargas HM, Jiménez VX, et al. Uterine sarcoma. IJOG 2000; 70(Suppl. 1).

  3. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 2014; 24(9): S55-S60.

  4. D’Angelo E, Prat J. Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol 2011; 25: 705-18.

  5. Sanaz Memarzadeh, Arno J Mundt, Steven C Plaxe. Uterine carcinosarcoma. Last literature review version 19.3: Fri Sep 30 00:00:00 GMT 2011 | This topic last updated: Mon Mar 29 00:00:00 GMT 2010.

  6. Goodrich SK, Knight J. Uterine sarcoma: ability of preoperative evaluation to identify malignancy and correct histology. Gynecol Oncol 2015; 137 (Suppl. 1): 97-8.

  7. NCCN Guidelines Version 3.2012- Endometrial carcinoma. (Accessed 19 September 2012). Available in: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

  8. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecologic Oncology 2010; 116(1): 131-9.

  9. Kosary CL. Chapter 15: Cancer of the corpus uteri. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (Eds). SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH. Bethesda, MD, 2007. Pub. No. 07-6215. (Accessed 12 October 2010) Available at: file://seer.cancer.gov/publications/survival/surv_corpus_uteri.pdf

  10. Shin-Wha Lee, Taek Sang Lee, Dae Gy Hong, Jae Hong No, Dong Choon Park, Jae Man Bae, et al. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol 2017; 28(1): e12.

  11. Vargas-Hernández VM. Lesiones premalignas, cáncer endometrial y cáncer del cuerpo uterino. En: Delgado Urdapilleta J, Fernandez del Castillo C, editores. Ginecología y reproducción humana. Temas selectos. México: COMEGO; 2006.

  12. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104(3): 177-8.

  13. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. Seventh edition. New York: Springer, Inc.; 2010.

  14. FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014; 125(2): 97-8.

  15. Gonzalez BJ, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, er al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol 2010; 116(3): 419-23.

  16. Murray S, Linardou H, Mountzios G, Manoloukos M, Markaki S, Eleutherakis-Papaiakovou E, et al. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010; 686(1-2): 68-73.

  17. De Jong RA, Nijman HW, Wilbrandi TF, Reyners AK, Boezen HM, Hollema H, et al. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial component. Mod Pathol. 2011; 24(10): 1368-79.

  18. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, et al. Tissue-specific signatures of activating PI3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011; 121(1): 212-7.

  19. Garg G, Shah J, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010; 20: 888-94.

  20. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008; 27(3): 326-32.

  21. D’Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009; 40(11): 1571-85.

  22. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009; 54(3): 355-64.

  23. Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinomas (malignant mixed Müllerian tumours): a critical literature review. Arch Gynecol Obstet 2010; 282(6): 659-64.

  24. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, et al. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer 2011; 21(3): 517-22.

  25. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 2010; 28(16): 2727-31.

  26. Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Ann Oncol 2013; 24(4): 1099-04.

  27. Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013; 2: CD006812.

  28. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group phase Il trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010; 117(2): 248-54.

  29. Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010; 76(3): 728-34.




2020     |     www.medigraphic.com